Skip to content
Nonprofiteer
← NATIONAL PEDIATRIC CANCER FOUNDATION INC

Form 990 for tax year 2024

Filed by NATIONAL PEDIATRIC CANCER FOUNDATION INC.

Totals

Total revenue
$4,449,969
Total expenses
$5,723,050
Contributions and grants received
$4,219,467
Grants paid
$3,441,620
Program service revenue
$0
Investment income
$87,081
Other revenue
$143,421
Total assets, end of year
$6,202,847
Total liabilities, end of year
$1,059,559
Net assets or fund balances, end of year
$5,143,288
Program services expenses (Part IX)
$5,120,886
Management and general expenses
$246,144
Fundraising expenses
$356,020
Program service expenses (Part III)
$5,120,886

Program services were 89.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c , Fundraising events

    $861,586

  • 1f , All other contributions, gifts and grants

    $3,357,881

  • 1g , Noncash contributions included above

    $10,622

  • 3 , Investment income

    total $129,377 · excluded $129,377

  • 7a , Gross sales of assets other than inventory

    securities $963,645

  • 7b , Less cost or other basis and sales expenses

    securities $1,005,941

  • 7c , Gain or loss

    securities -$42,296

  • 7d , Net gain or loss

    total -$42,296 · excluded -$42,296

  • 8a , Fundraising events: gross income

    $1,917,654

  • 8a , Fundraising events: contributions included on line 1c

    $861,586

  • 8b , Fundraising events: direct expenses

    $1,782,971

  • 8c , Net income from fundraising events

    total $134,683 · excluded $134,683

  • 11a , Other revenue: MISCELLANEOUS REVNEUE

    total $8,738 · excluded $8,738

  • 11e , Other revenue, total

    $8,738

Functional expenses

Part IX, the statement of functional expenses.

  • 1 , Grants to domestic organizations and governments

    total $3,429,303 · program services $3,429,303

  • 2 , Grants to domestic individuals

    total $12,317 · program services $12,317

  • 5 , Compensation of officers, directors and key employees

    total $492,986 · program services $414,454 · management and general $42,970 · fundraising $35,562

  • 7 , Other salaries and wages

    total $1,023,485 · program services $860,446 · management and general $89,208 · fundraising $73,831

  • 9 , Other employee benefits

    total $52,634 · program services $44,249 · management and general $4,588 · fundraising $3,797

  • 10 , Payroll taxes

    total $116,472 · program services $97,918 · management and general $10,152 · fundraising $8,402

  • 11f , Fees: investment management

    total $28,270 · management and general $28,270

  • 11g , Fees: other

    total $36,032 · program services $1,566 · management and general $29,708 · fundraising $4,758

  • 12 , Advertising and promotion

    total $132,228 · program services $1,207 · management and general $88 · fundraising $130,933

  • 13 , Office expenses

    total $19,313 · program services $8,968 · management and general $5,803 · fundraising $4,542

  • 14 , Information technology

    total $108,836 · program services $89,179 · management and general $12,673 · fundraising $6,984

  • 16 , Occupancy

    total $49,241 · program services $42,417 · management and general $3,420 · fundraising $3,404

  • 17 , Travel

    total $17,857 · program services $2,500 · management and general $3,807 · fundraising $11,550

  • 19 , Conferences, conventions and meetings

    total $1,623 · program services $117 · management and general $351 · fundraising $1,155

  • 20 , Interest

    total $28,378 · program services $24,984 · management and general $1,677 · fundraising $1,717

  • 22 , Depreciation, depletion and amortization

    total $52,167 · program services $45,961 · management and general $3,121 · fundraising $3,085

  • 23 , Insurance

    total $31,415 · program services $24,845 · management and general $4,859 · fundraising $1,711

  • 24a , Other expenses: ONLINE TRANSACTION FEES

    total $44,788 · program services $0 · management and general $3,154 · fundraising $41,634

  • 24b , Other expenses: POSTAGE AND SHIPPING

    total $27,022 · program services $5,864 · management and general $656 · fundraising $20,502

  • 24c , Other expenses: CONTRACT LABOR

    total $12,583 · program services $11,070 · management and general $771 · fundraising $742

  • 24d , Other expenses: PRINTING AND REPRODUCTI

    total $4,092 · program services $3,521 · management and general $336 · fundraising $235

  • 24e , All other expenses

    total $2,008 · management and general $532 · fundraising $1,476

Balance sheet

Part X, book values.

  • 1 , Cash, non-interest-bearing

    beginning of year $1,273,888 · end of year $581,005

  • 2 , Savings and temporary cash investments

    end of year $602,727

  • 3 , Pledges and grants receivable

    beginning of year $32,475 · end of year $21,455

  • 9 , Prepaid expenses and deferred charges

    beginning of year $193,136 · end of year $134,416

  • 10a , Land, buildings and equipment: cost or other basis

    $1,692,819

  • 10b , Land, buildings and equipment: accumulated depreciation

    $178,174

  • 10c , Land, buildings and equipment, net

    beginning of year $1,510,693 · end of year $1,514,645

  • 11 , Investments: publicly traded securities

    beginning of year $3,750,447 · end of year $3,050,583

  • 15 , Other assets

    beginning of year $270,970 · end of year $298,016

  • 17 , Accounts payable and accrued expenses

    beginning of year $76,027 · end of year $126,715

  • 18 , Grants payable

    end of year $272,704

  • 19 , Deferred revenue

    beginning of year $189,597 · end of year $37,743

  • 23 , Secured mortgages and notes payable

    beginning of year $647,870 · end of year $608,148

  • 25 , Other liabilities

    beginning of year $17,379 · end of year $14,249

  • 27 , Net assets without donor restrictions

    beginning of year $5,418,356 · end of year $4,475,544

  • 28 , Net assets with donor restrictions

    beginning of year $682,380 · end of year $667,744

Mission and programs · 2024

Mission

NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE.

Activities or mission (Part I)

THE NPCF IS DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER.

  • THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 40 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA); BRAIN CANCER TRIALS (MEDULLOBLASTOMA, HIGH-GRADE GLIOMA); SOLID STATE TUMORS1. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3-YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 2. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.3. A MULTI-INSTITUTION STUDY OF TGFB IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WITH THIS TREATMENT.4. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS5. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVAL AT 4 MONTHS AFTER INITIATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 6. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.7. RNA LIPID PARTICLES TARGETING PEDIATRIC RECURRENT INTRACRANIAL MALIGNANCIES AND OTHER SYSTEMIC SOLID TUMORS - THIS TRIAL TESTS THE SAFETY, IMMUNE EFFECTS, AND POTENTIAL EFFECTIVENESS OF RNA-LOADED LIPID NANOPARTICLES (RNA-LP) VACCINES IN PATIENTS WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (PHGG), A TYPE OF BRAIN CANCER, AND RECURRENT OSTEOSARCOMA (OSA), A TYPE OF BONE CANCER. 8. OPEN-LABEL, COHORT-SEQUENTIAL DOSE-ESCALATION AND DOSE-CONFIRMATION PHASE 1-2 CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DOMATINOSTAT IN COMBINATION WITH SIROLIMUS IN ADOLESCENTS AND ADULTS WITH RELAPSED, REFRACTORY SARCOMA AND OSTEOSARCOMA - THIS TRIAL TESTS THE SAFETY AND EFFECTIVENESS OF TWO DRUGS, DOMATINOSTAT AND SIROLIMUS, USED TOGETHER IN PATIENTS WITH OSTEOSARCOMA AND OTHER SARCOMAS THAT HAVE COME BACK OR DON'T RESPOND TO OTHER TREATMENTS. 9. ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3'UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS - THIS STUDY HAS IDENTIFIED A NOVEL TECHNOLOGY THAT CAN CONTROL AND DEGRADE A SPECIFIC C-MYC GENE (KNOWN AS THE MASTER REGULATOR) ACROSS MANY TYPES OF CANCERS. SINCE C-MYC IS DETECTED IN 74% OF HUMAN CANCERS, THE ABILITY TO DEGRADE AND ATTACK THIS COMMON LINK HAS THE POTENTIAL TO TRANSFORM THE TREATMENT OF CANCER. 10. TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOLOGY - THIS STUDY WILL USE QUANTUM MECHANICS TO PRECISELY TARGET SPECIFIC TUMOR CELLS WITHOUT HARMING NORMAL CELLS. THE METHOD USES CONVENTIONAL CLINICAL PROCEDURES IN A NOVEL COMBINATION WITHIN A WEAK MAGNETIC FIELD, AKIN TO A REFRIGERATOR MAGNET'S, SUCH THAT IF SUCCESSFUL IT COULD BE INTRODUCED INTO ANY HOSPITAL WITHOUT MAJOR INFRASTRUCTURAL, FINANCIAL OR PROCEDURAL DIFFICULT TO TREAT CHILDREN AND EVEN INFANTS WITH MEDULLOBLASTOMA, THE MOST COMMON CHILDHOOD BRAIN CANCER.

    Expenses $5,120,886 · Grants $3,441,620

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Albert Silva

    CHAIRMAN OF THE BOARD

    Total calculated
    $0
    Hours/week
    2
  • Michael Levin

    PAST CHAIR

    Total calculated
    $0
    Hours/week
    2
  • Richard Huff

    VICE CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Alex Sullivan

    VICE CHAIRMAN

    Total calculated
    $0
    Hours/week
    2
  • Jeremy Persinger

    TREASURER

    Total calculated
    $0
    Hours/week
    2
  • John Fitzpatrick

    SECRETARY

    Total calculated
    $0
    Hours/week
    2
  • Michael Weigner

    ASSISTANT SECRETARY

    Total calculated
    $0
    Hours/week
    2
  • Melissa Dunkel

    CO-FOUNDER AT LARGE

    Total calculated
    $0
    Hours/week
    1
  • Jim Bassil

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Bb Abbott

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • David Boyington

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Chris Carrere

    DIRECTOR AT LARGE

    Total calculated
    $0
    Hours/week
    1
  • Carrie Charles

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Chad Harrod

    EMERITUS

    Total calculated
    $0
    Hours/week
    1
  • Joseph Lamphier

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Jay Langford

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Jeff Maxwell

    DIRECTOR AT LARGE

    Total calculated
    $0
    Hours/week
    1
  • Mark McHugh

    DIRECTOR AT LARGE

    Total calculated
    $0
    Hours/week
    1
  • Angela North

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Marco Schnabl

    DIRECTOR AT LARGE

    Total calculated
    $0
    Hours/week
    1
  • Dawn Siler-Nixon

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Ashlie Teeling

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • David Frazer

    CEO

    Total calculated
    $210,377
    From this org
    $210,377
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $191,783
    Bonus
    $18,594
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $210,377
  • Dawn Zachman

    COO

    Total calculated
    $119,939
    From this org
    $119,939
    From related orgs
    $0
    Other
    $0
    Hours/week
    40
  • Robert Martin

    CFO THRU OCTOBER 2024

    Total calculated
    $132,178
    From this org
    $132,178
    From related orgs
    $0
    Other
    $0
    Hours/week
    40
  • Jennifer Finnemore

    CFO START OCTOBER 2024

    Total calculated
    $30,492
    From this org
    $30,492
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Written employment contract
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Fundraising events (Part II)
Line Event 1 FASHION FUNDS THE CURE Event 2 FISHING FUNDS THE CURE Other events 8 events Total
Gross receipts (line 1) $1,839,959 $563,749 $375,532 $2,779,240
Less contributions (line 2) $726,238 $81,345 $54,003 $861,586
Gross income (line 3) $1,113,721 $482,404 $321,529 $1,917,654
Cash prizes (line 4) — — — —
Noncash prizes (line 5) — — — —
Rent and facility costs (line 6) $37,500 $1,305 $17,300 $56,105
Food and beverages (line 7) — — — —
Entertainment (line 8) — — — —
Other direct expenses (line 9) $957,861 $429,010 $339,995 $1,726,866
Direct expenses (line 10)
$1,782,971
Net income (line 11)
$134,683

Provenance

Return type
form_990
Tax year
2024
Filed
9 October 2025
IRS schema version
2024v5.2
Source object
202532909349300108

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.